Research addresses chromosomal imbalance in embryos

NewsGuard 100/100 Score

Joint research between the University of Kent's Professor Darren Griffin, London Bridge Fertility Centre and BlueGnome Ltd has addressed chromosomal imbalance in embryos, a condition that is currently the major cause of pregnancy loss in IVF.

Published by the Journal of Medical Genetics, the team's research involved screening 164 eggs for aneuploidy, or the condition of a cell containing an incorrect number of chromosomes. Consequently, they discovered that, contrary to the widely held belief that aneuploidy in human embryos arises from incorrect separation of whole chromosomes (termed non-disjunction) during formation of an egg, human aneuploidy is likely to be due to an alternative method that involves the premature splitting and separation of individual chromosomes into their two halves. 

Professor Griffin, a specialist in genetics at the University's School of Biosciences, explained that the screening was enabled by BlueGnome's 24sure platform, a technique that assesses aneuploidy though thousands of individual measurements across all chromosomes. 'The quantification is sufficiently accurate to distinguish between the gain or loss of whole or half chromosomes,' he said. 'Therefore an assessment of which method leads to aneuploidy - i.e. the gain or loss - can be made.' 

Professor Griffin also explained that 'the wisdom that non-disjunction is the primary mechanism leading to human aneuploidy should be reconsidered and further investigations will needed to look at the causes of these mechanistic errors in this vital area of embryo development.' 

Nick Haan, CEO of BlueGnome, said: 'This paper illustrates the power of 24sure technology and the vital need to detect even imbalance of chromatids when screening eggs to check that they are suitable for IVF.'

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New research sheds light on how GLP-1 obesity drugs may change food cravings